Patrick Soon-Shiong (Evan Vucci/AP Images)

Up­dat­ed: Ar­bi­tra­tor awards $157M to Soon-Sh­iong's Im­mu­ni­ty­Bio in dis­pute with Sor­ren­to

Sor­ren­to Ther­a­peu­tics’ years­long bat­tle with Nant­Cell and NAN­Ti­body has come to an ar­bi­tra­tion award, but ad­di­tion­al le­gal pro­ceed­ings cen­tered around a “catch-and-kill” scheme re­main pend­ing.

On Fri­day, the ar­bi­tra­tor in the dis­pute be­tween Sor­ren­to and Nant­Cell and Im­munother­a­py NAN­Ti­body LLC is­sued an award that grants con­trac­tu­al dam­ages and pre-award in­ter­est.

The ar­bi­tra­tor award­ed Nant­Cell (part of bil­lion­aire Patrick Soon-Sh­iong’s Im­mu­ni­ty­Bio) near­ly $157 mil­lion and NAN­Ti­body close to $17 mil­lion. Post-award, pre­judg­ment in­ter­est will ac­crue at 9% per an­num, ac­cord­ing to an SEC fil­ing sent in by Sor­ren­to.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.